Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | Director | May 20, 2026 | May 22, 2026 |
| CELGENE CORP /DE/CELG · Entity 15781 | SEE REMARKS | July 30, 2018 | August 01, 2018 |
| Merck & Co., Inc.MRK · Entity 2807 | Exe V-P & CFO | February 24, 2014 | February 26, 2014 |
| YIELD10 BIOSCIENCE, INC.YTEN · Entity 88195 | Director | May 22, 2019 | May 23, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date May 20, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,446 |
Reported balance
After 2026-05-20 transaction · row 1
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 671 · Balance 1,446 F1: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $298.48 · Expires 2036-05-20 | Direct | 1,441 |
Reported balance
After 2026-05-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-20 · Grant · Acquired 1,441 · Balance 1,441 F2: The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
F2: The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
CELGENE CORP /DE/
Report date July 30, 2018 · Filed August 01, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.91 · Expires 2028-07-30 | Direct | 20,285 |
Reported balance
After 2018-07-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-07-30 · Grant · Acquired 20,285 · Balance 20,285 F2: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F1: Option is immediately exercisable and will vest in four equal annual installments commencing on July 30, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Option is immediately exercisable and will vest in four equal annual installments commencing on July 30, 2019.
F2: The option was issued pursuant to the Company's 2017 Stock Incentive Plan.
Merck & Co., Inc.
Report date February 24, 2014 · Filed February 26, 2014
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 149,553.902 |
Reported balance
After 2014-02-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2014-02-24 · Grant · Acquired 18,662 · Balance 149,553.902 F1: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 03/31/2011. Performance shares were paid out at 86 percent of target awards. F2: Holdings include shares acquired in dividend reinvestment transactions. |
Filing footnotes · ownership attribution and instrument terms
F1: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 03/31/2011. Performance shares were paid out at 86 percent of target awards.
F2: Holdings include shares acquired in dividend reinvestment transactions.
YIELD10 BIOSCIENCE, INC.
Report date May 22, 2019 · Filed May 23, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.90 · Expires 2029-05-22 | Direct | 10,000 |
Reported balance
After 2019-05-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-05-22 · Grant · Acquired 10,000 · Balance 10,000 F1: These options were issued to the Reporting Person as the annual option grant to non-employee directors pursuant to the Issuer's Director Compensation Policy for services to be rendered to the Issuer as a member of its Board of Directors and/or a committee thereof. F2: These options will vest and become exercisable in equal quarterly installments over 4 years from 5/22/19, beginning on 8/22/2019 and ending on 5/22/2023. |
Filing footnotes · ownership attribution and instrument terms
F1: These options were issued to the Reporting Person as the annual option grant to non-employee directors pursuant to the Issuer's Director Compensation Policy for services to be rendered to the Issuer as a member of its Board of Directors and/or a committee thereof.
F2: These options will vest and become exercisable in equal quarterly installments over 4 years from 5/22/19, beginning on 8/22/2019 and ending on 5/22/2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2026 Filed May 22, 2026 20:12 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (Right to Buy) · Derivative | 1,441 | $0.00 Strike: $298.48 | $0.00 |
DisclosureSEC source: 0001178670-26-000038 · form4.xml · derivative · entry 2 KELLOGG PETER N · CIK 0001226287 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,441 Underlying: Common Stock · 1,441 shares Expires 2036-05-20 F2 · derivative.exercise_date: The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:12 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 671 | $0.00 | $0.00 |
DisclosureSEC source: 0001178670-26-000038 · form4.xml · nonDerivative · entry 1 KELLOGG PETER N · CIK 0001226287 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,446 F1 · shares: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| May 08, 2025 Filed May 12, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 1,558 | $0.00 Strike: $258.35 | $0.00 |
DisclosureSEC source: 0001735276-25-000064 · edgardoc.xml · derivative · entry 2 KELLOGG PETER N · CIK 0001226287 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,558 Underlying: Common Stock · 1,558 shares Expires 2035-05-08 F2 · derivative.exercise_date: The stock option vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| May 08, 2025 Filed May 12, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 775 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-25-000064 · edgardoc.xml · nonDerivative · entry 1 KELLOGG PETER N · CIK 0001226287 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 775 F1 · shares: These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| May 16, 2024 Filed May 20, 2024 20:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 5,228 | $0.00 Strike: $151.22 | $0.00 |
DisclosureSEC source: 0001735276-24-000054 · edgardoc.xml · derivative · entry 1 KELLOGG PETER N · CIK 0001226287 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,228 Underlying: Common Stock · 5,228 shares Expires 2034-05-16 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 21:12 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 4,948 | $0.00 Strike: $194.34 | $0.00 |
DisclosureSEC source: 0001735276-23-000036 · edgardoc.xml · derivative · entry 1 KELLOGG PETER N · CIK 0001226287 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,948 Underlying: Common Stock · 4,948 shares Expires 2033-03-07 F1 · derivative.exercise_date: The stock option will vest as to one third of the shares on each of the first, second and third anniversaries of the date of grant. Read SEC document |
| May 22, 2019 Filed May 23, 2019 16:33 UTC | YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001179110-19-006581 · edgar.xml · derivative · entry 1 KELLOGG PETER N · CIK 0001226287 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-05-22 F1 · shares: These options were issued to the Reporting Person as the annual option grant to non-employee directors pursuant to the Issuer's Director Compensation Policy for services to be rendered to the Issuer as a member of its Board of Directors and/or a committee thereof. F2 · derivative.exercise_date: These options will vest and become exercisable in equal quarterly installments over 4 years from 5/22/19, beginning on 8/22/2019 and ending on 5/22/2023. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 13:44 UTC | YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195 | GrantStock Option (right to buy) · Derivative | 6,128 | $0.76 Strike: $0.83 | $4,657.28 |
DisclosureSEC source: 0001179110-19-000156 · edgar.xml · derivative · entry 1 KELLOGG PETER N · CIK 0001226287 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,128 Underlying: Common Stock · 6,128 shares Expires 2028-12-31 F1 · shares: These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,687 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the fourth quarter of 2018. Read SEC document |
| September 28, 2018 Filed Oct 2, 2018 11:39 UTC | YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195 | GrantStock Option (right to buy) · Derivative | 3,512 | $1.33 Strike: $1.44 | $4,670.96 |
DisclosureSEC source: 0001179110-18-011809 · edgar.xml · derivative · entry 1 KELLOGG PETER N · CIK 0001226287 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,512 Underlying: Common Stock · 3,512 shares Expires 2028-09-28 F1 · shares: These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,687 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the third quarter of 2018. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 20,285 | $0.00 Strike: $88.91 | $0.00 |
DisclosureSEC source: 0001415889-18-001201 · form4-08012018_040806.xml · derivative · entry 1 KELLOGG PETER N · CIK 0001226287 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,285 Underlying: Common Stock · 20,285 shares Expires 2028-07-30 F2 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments commencing on July 30, 2019. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 15:08 UTC | YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195 | GrantStock Option (right to buy) · Derivative | 3,583 | $1.31 Strike: $1.41 | $4,693.73 |
DisclosureSEC source: 0001179110-18-009305 · edgar.xml · derivative · entry 1 KELLOGG PETER N · CIK 0001226287 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,583 Underlying: Common Stock · 3,583 shares Expires 2028-06-29 F1 · shares: These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,687 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the second quarter of 2018. Read SEC document |
| May 23, 2018 Filed May 25, 2018 10:50 UTC | YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001179110-18-007507 · edgar.xml · derivative · entry 1 KELLOGG PETER N · CIK 0001226287 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-05-23 F1 · shares: These options were issued to the Reporting Person as the annual option grant to non-employee directors pursuant to the Issuer's Director Compensation Policy for services to be rendered to the Issuer as a member of its Board of Directors and/or a committee thereof. F2 · derivative.exercise_date: These options will vest and become exercisable in equal quarterly installments over 4 years from 5/23/18, beginning on 8/23/2018 and ending on 5/23/2022. Read SEC document |
| May 08, 2018 Filed May 17, 2018 16:07 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 10,301 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-18-000762 · form4-05172018_010534.xml · derivative · entry 2 KELLOGG PETER N · CIK 0001226287 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,301 Underlying: Common Stock · 10,301 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F5 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F4 · derivative.exercise_date: The restricted stock units will fully vest on May 8, 2021. Vested shares will be delivered to the reporting person promptly after the vesting date. F4 · derivative.expiration_date: The restricted stock units will fully vest on May 8, 2021. Vested shares will be delivered to the reporting person promptly after the vesting date. Read SEC document |
| May 08, 2018 Filed May 17, 2018 16:07 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (Right to Buy) · Derivative | 20,285 | Not disclosed Strike: $83.13 | Not disclosed |
DisclosureSEC source: 0001415889-18-000762 · form4-05172018_010534.xml · derivative · entry 1 KELLOGG PETER N · CIK 0001226287 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,285 Underlying: Common Stock · 20,285 shares Expires 2028-05-08 F2 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal installments, commencing on May 8, 2019. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:34 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000696 · form4-05082018_010529.xml · derivative · entry 4 KELLOGG PETER N · CIK 0001226287 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units granted to the reporting person on May 4, 2015 have vested and settled for shares of the Company's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: The restricted stock units granted to the reporting person on May 4, 2015 have vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: The restricted stock units granted to the reporting person on May 4, 2015 have vested and settled for shares of the Company's common stock. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:34 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Tax withholdingCommon Stock | 1,622 | $86.89 | $140,935.58 |
DisclosureSEC source: 0001415889-18-000696 · form4-05082018_010529.xml · nonDerivative · entry 2 KELLOGG PETER N · CIK 0001226287 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,209 Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:34 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000696 · form4-05082018_010529.xml · nonDerivative · entry 1 KELLOGG PETER N · CIK 0001226287 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,831 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units granted to the reporting person on May 4, 2015 have vested and settled for shares of the Company's common stock. Read SEC document |
| March 29, 2018 Filed Apr 2, 2018 17:29 UTC | YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195 | GrantStock Option (right to buy) · Derivative | 2,958 | $1.58 Strike: $1.95 | $4,673.64 |
DisclosureSEC source: 0001179110-18-005076 · edgar.xml · derivative · entry 1 KELLOGG PETER N · CIK 0001226287 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,958 Underlying: Common Stock · 2,958 shares Expires 2028-03-29 F1 · shares: These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,687 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the first quarter of 2018. Read SEC document |
| February 17, 2018 Filed Feb 20, 2018 17:03 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionPerformance Stock Unit · Derivative | 7,283 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011404 · doc4.xml · derivative · entry 4 KELLOGG PETER N · CIK 0001226287 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,283 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The performance stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: The performance stock units granted to the reporting person on February 13, 2018 vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: The performance stock units granted to the reporting person on February 13, 2018 vested and settled for shares of the Company's common stock. Read SEC document |
| February 17, 2018 Filed Feb 20, 2018 17:03 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Tax withholdingCommon Stock | 2,329 | $95.26 | $221,860.54 |
DisclosureSEC source: 0001209191-18-011404 · doc4.xml · nonDerivative · entry 2 KELLOGG PETER N · CIK 0001226287 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,331 Read SEC document |
| February 17, 2018 Filed Feb 20, 2018 17:03 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 7,283 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011404 · doc4.xml · nonDerivative · entry 1 KELLOGG PETER N · CIK 0001226287 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The performance stock units granted to the reporting person on February 13, 2018 vested and settled for shares of the Company's common stock. Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 16:06 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantPerformance Stock Unit · Derivative | 7,283 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-010350 · doc4.xml · derivative · entry 1 KELLOGG PETER N · CIK 0001226287 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,283 Underlying: Common Stock · 7,283 shares Expires not disclosed F1 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of the Company's common stock. F2 · price: The performance stock units were issued pursuant to the Company's 2017 Stock Incentive Plan and will vest on February 17, 2018. F2 · derivative.exercise_date: The performance stock units were issued pursuant to the Company's 2017 Stock Incentive Plan and will vest on February 17, 2018. F2 · derivative.expiration_date: The performance stock units were issued pursuant to the Company's 2017 Stock Incentive Plan and will vest on February 17, 2018. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 16:38 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 13,377 | $0.00 Strike: $103.26 | $0.00 |
DisclosureSEC source: 0001209191-18-006224 · doc4.xml · derivative · entry 1 KELLOGG PETER N · CIK 0001226287 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,377 Underlying: Common Stock · 13,377 shares Expires 2028-01-29 F2 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: Option is immediately exercisable and will vest as follows: 3,344 shares on January 29, 2019; 3,344 shares on January 29, 2020; 3,344 shares on January 29, 2021; and 3,345 shares on January 29, 2022. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 16:53 UTC | YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195 | GrantStock Option (right to buy) · Derivative | 6,726 | $1.39 Strike: $1.77 | $9,349.14 |
DisclosureSEC source: 0001179110-18-000316 · edgar.xml · derivative · entry 1 KELLOGG PETER N · CIK 0001226287 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,726 Underlying: Common Stock · 6,726 shares Expires 2027-12-29 F1 · shares: These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $9,375 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the fourth quarter of 2017. Read SEC document |
| December 19, 2017 Filed Dec 20, 2017 16:04 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 3,410 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-066620 · doc4.xml · derivative · entry 4 KELLOGG PETER N · CIK 0001226287 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,410 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All of the restricted stock units granted to the reporting person on December 19, 2014 vested and settled for shares of the Company's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to The Celgene Corporation 2017 Stock Incentive Plan. F1 · derivative.exercise_date: All of the restricted stock units granted to the reporting person on December 19, 2014 vested and settled for shares of the Company's common stock. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| December 19, 2017 Filed Dec 20, 2017 16:04 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Tax withholdingCommon Stock | 1,768 | $107.06 | $189,282.08 |
DisclosureSEC source: 0001209191-17-066620 · doc4.xml · nonDerivative · entry 2 KELLOGG PETER N · CIK 0001226287 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,377 Read SEC document |
| December 19, 2017 Filed Dec 20, 2017 16:04 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 3,410 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-066620 · doc4.xml · nonDerivative · entry 1 KELLOGG PETER N · CIK 0001226287 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All of the restricted stock units granted to the reporting person on December 19, 2014 vested and settled for shares of the Company's common stock. Read SEC document |
| November 28, 2017 Filed Nov 30, 2017 16:20 UTC | YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195 | GrantStock Option (right to buy) · Derivative | 5,258 | $0.00 Strike: $2.34 | $0.00 |
DisclosureSEC source: 0001179110-17-014725 · edgar.xml · derivative · entry 1 KELLOGG PETER N · CIK 0001226287 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,258 Underlying: Common Stock · 5,258 shares Expires 2027-11-28 F1 · shares: These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the third quarter of 2017. F2 · balance_after: All share numbers reported reflect the 1-for-10 reverse stock split effected on May 30, 2017. Read SEC document |
| October 30, 2017 Filed Oct 31, 2017 16:10 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 3,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-058430 · doc4.xml · derivative · entry 6 KELLOGG PETER N · CIK 0001226287 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,666 Underlying: Common Stock · 3,666 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F7 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F6 · derivative.exercise_date: The restricted stock units will fully vest on October 30, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. F6 · derivative.expiration_date: The restricted stock units will fully vest on October 30, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. Read SEC document |
| October 30, 2017 Filed Oct 31, 2017 16:10 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 30,911 | Not disclosed Strike: $100.97 | Not disclosed |
DisclosureSEC source: 0001209191-17-058430 · doc4.xml · derivative · entry 5 KELLOGG PETER N · CIK 0001226287 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,911 Underlying: Common Stock · 30,911 shares Expires 2027-10-30 F4 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F3 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments, commencing on October 30, 2018. Read SEC document |
| October 27, 2017 Filed Oct 31, 2017 16:10 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 2,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-058430 · doc4.xml · derivative · entry 4 KELLOGG PETER N · CIK 0001226287 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All of the restricted stock units granted to the reporting person on October 27, 2014 vested and settled for shares of the Company's common stock. F1 · price: All of the restricted stock units granted to the reporting person on October 27, 2014 vested and settled for shares of the Company's common stock. F1 · derivative.exercise_date: All of the restricted stock units granted to the reporting person on October 27, 2014 vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: All of the restricted stock units granted to the reporting person on October 27, 2014 vested and settled for shares of the Company's common stock. Read SEC document |
| October 27, 2017 Filed Oct 31, 2017 16:10 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Tax withholdingCommon Stock | 1,088 | $98.17 | $106,808.96 |
DisclosureSEC source: 0001209191-17-058430 · doc4.xml · nonDerivative · entry 2 KELLOGG PETER N · CIK 0001226287 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,735 F2 · shares: This amount reflects shares withheld by the Company for the payment of taxes on the vested shares. Read SEC document |
| October 27, 2017 Filed Oct 31, 2017 16:10 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 2,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-058430 · doc4.xml · nonDerivative · entry 1 KELLOGG PETER N · CIK 0001226287 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,823 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All of the restricted stock units granted to the reporting person on October 27, 2014 vested and settled for shares of the Company's common stock. Read SEC document |
| August 01, 2017 Filed Aug 2, 2017 16:37 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-047122 · doc4.xml · derivative · entry 5 KELLOGG PETER N · CIK 0001226287 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All of the restricted stock units granted to the reporting person on August 1, 2014 vested and settled for shares of the Company's common stock. F1 · price: All of the restricted stock units granted to the reporting person on August 1, 2014 vested and settled for shares of the Company's common stock. F1 · derivative.exercise_date: All of the restricted stock units granted to the reporting person on August 1, 2014 vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: All of the restricted stock units granted to the reporting person on August 1, 2014 vested and settled for shares of the Company's common stock. Read SEC document |
| August 01, 2017 Filed Aug 2, 2017 16:37 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Tax withholdingCommon Stock | 31,110 | $135.18 | $4,205,449.80 |
DisclosureSEC source: 0001209191-17-047122 · doc4.xml · nonDerivative · entry 2 KELLOGG PETER N · CIK 0001226287 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,723 F2 · shares: This amount reflects shares withheld by the Company for the payment of taxes on the vested shares. Read SEC document |
| August 01, 2017 Filed Aug 2, 2017 16:37 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-047122 · doc4.xml · nonDerivative · entry 1 KELLOGG PETER N · CIK 0001226287 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All of the restricted stock units granted to the reporting person on August 1, 2014 vested and settled for shares of the Company's common stock. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 16:37 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 13,376 | $0.00 Strike: $135.41 | $0.00 |
DisclosureSEC source: 0001209191-17-047122 · doc4.xml · derivative · entry 4 KELLOGG PETER N · CIK 0001226287 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,376 Underlying: Common Stock · 13,376 shares Expires 2027-07-31 F4 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F3 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments commencing on July 31, 2018. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 16:20 UTC | YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195 | GrantCommon Stock | 1,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-009987 · edgar.xml · nonDerivative · entry 1 KELLOGG PETER N · CIK 0001226287 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,302 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the second quarter of 2017. F2 · balance_after: All share numbers reported reflect the 1-for-10 reverse stock split effected on May 30, 2017. Read SEC document |
| May 24, 2017 Filed May 26, 2017 16:07 UTC | YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0001179110-17-008072 · edgar.xml · derivative · entry 2 KELLOGG PETER N · CIK 0001226287 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-05-24 F2 · shares: These options were issued to the Reporting Person as the annual option grant to non-employee directors pursuant to the Issuer's Director Compensation Policy for services to be rendered to the Issuer as a member of its Board of Directors and/or a committee thereof. Read SEC document |
| May 24, 2017 Filed May 26, 2017 16:07 UTC | YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195 | GrantCommon Stock | 22,321 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-008072 · edgar.xml · nonDerivative · entry 1 KELLOGG PETER N · CIK 0001226287 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,821 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the first quarter of 2017. Read SEC document |
| May 01, 2017 Filed May 2, 2017 16:19 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 6,763 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-029188 · doc4.xml · derivative · entry 2 KELLOGG PETER N · CIK 0001226287 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,763 Underlying: Common Stock · 6,763 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F4 · price: The restricted stock units were issued pursuant to the Company's 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015) and will vest on May 1, 2020. Vested shares will be delivered to the reporting person on the vesting date. F4 · derivative.exercise_date: The restricted stock units were issued pursuant to the Company's 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015) and will vest on May 1, 2020. Vested shares will be delivered to the reporting person on the vesting date. F4 · derivative.expiration_date: The restricted stock units were issued pursuant to the Company's 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015) and will vest on May 1, 2020. Vested shares will be delivered to the reporting person on the vesting date. Read SEC document |
| May 01, 2017 Filed May 2, 2017 16:19 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 13,376 | $0.00 Strike: $124.06 | $0.00 |
DisclosureSEC source: 0001209191-17-029188 · doc4.xml · derivative · entry 1 KELLOGG PETER N · CIK 0001226287 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,376 Underlying: Common Stock · 13,376 shares Expires 2027-05-01 F2 · price: The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015). F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments commencing on May 1, 2018. Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 17:08 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Tax withholdingCommon Stock | 7,617 | $117.02 | $891,341.34 |
DisclosureSEC source: 0001209191-17-011558 · doc4.xml · nonDerivative · entry 2 KELLOGG PETER N · CIK 0001226287 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,833 Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 17:08 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantCommon Stock | 14,684 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-011558 · doc4.xml · nonDerivative · entry 1 KELLOGG PETER N · CIK 0001226287 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,450 F1 · shares: Represents shares of common stock relating to the 2014-2016 Long Term Incentive Plan and issued under the Celgene Corporation 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015). Read SEC document |
| January 30, 2017 Filed Jan 31, 2017 16:23 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 12,981 | Not disclosed Strike: $113.18 | Not disclosed |
DisclosureSEC source: 0001209191-17-006365 · doc4.xml · derivative · entry 1 KELLOGG PETER N · CIK 0001226287 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,981 Underlying: Common Stock · 12,981 shares Expires 2027-01-30 F2 · price: The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015). F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments commencing on January 30, 2018. F2 · ownership.direct: The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015). Read SEC document |
| October 31, 2016 Filed Nov 2, 2016 16:14 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 5,609 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-147899 · doc4.xml · derivative · entry 2 KELLOGG PETER N · CIK 0001226287 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,609 Underlying: Common Stock · 5,609 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F4 · derivative.exercise_date: The restricted stock units were issued pursuant to the Company's 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015) and will vest on October 31, 2019. Vested shares will be delivered to the reporting person on the vesting date. F4 · derivative.expiration_date: The restricted stock units were issued pursuant to the Company's 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015) and will vest on October 31, 2019. Vested shares will be delivered to the reporting person on the vesting date. Read SEC document |
| October 31, 2016 Filed Nov 2, 2016 16:14 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 32,104 | $0.00 Strike: $102.18 | $0.00 |
DisclosureSEC source: 0001209191-16-147899 · doc4.xml · derivative · entry 1 KELLOGG PETER N · CIK 0001226287 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,104 Underlying: Common Stock · 32,104 shares Expires 2026-10-31 F2 · price: The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015). F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments commencing on October 31, 2017. Read SEC document |
| February 24, 2014 Filed Feb 26, 2014 19:26 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 18,662 | $56.18 | $1,048,431.16 |
DisclosureSEC source: 0001225208-14-006295 · doc4.xml · nonDerivative · entry 1 KELLOGG PETER N · CIK 0001226287 · Exe V-P & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,553.902 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 03/31/2011. Performance shares were paid out at 86 percent of target awards. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 13, 2013 Filed Nov 14, 2013 16:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 40,000 | $47.59 | $1,903,600.00 |
DisclosureSEC source: 0001225208-13-023472 · doc4.xml · derivative · entry 3 KELLOGG PETER N · CIK 0001226287 · Exe V-P & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2013-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: 40,000 Restricted Stock Units vested on November 13, 2010 (reduced by 18,540 withheld for taxes) and 40,000 vested on November 13, 2013 (reduced by 20,740 withheld for taxes). Read SEC document |
| November 13, 2013 Filed Nov 14, 2013 16:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 20,740 | $47.59 | $987,016.60 |
DisclosureSEC source: 0001225208-13-023472 · doc4.xml · nonDerivative · entry 2 KELLOGG PETER N · CIK 0001226287 · Exe V-P & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,891.902 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.